Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Precision Therapeutics Forms Scientific Advisory Board to Advance its Strategy in the Precision Medicine Sector
Marc Malandro PhD Named First Member of Scientific Advisory Board MINNEAPOLIS , Sept. 06, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, is pleased
View HTML
Toggle Summary Precision Therapeutics Forms TumorGenesis Inc. Subsidiary to Focus on the Next Generation of Patient Derived Tumor Models
MINNEAPOLIS , Feb. 27, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), formerly Skyline Medical (NASDAQ:SKLN), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today it has formed a wholly
View HTML
Toggle Summary Precision Therapeutics Granted European Patent for its Automated, Direct-to-Drain Medical Fluid Disposal System
MINNEAPOLIS , July 12, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, is pleased to announce that on July 11, 2018 the European Patent Office
View HTML
Toggle Summary Precision Therapeutics Inc. is Excited to Announce a Special Meeting of Stockholders and Commencement of Registered Exchange Offer
MINNEAPOLIS , Feb. 19, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision”) today announced the effectiveness of its Form S-4 registration statement, the establishment of the date of its special meeting of stockholders in connection with the proposed business
View HTML
Toggle Summary Precision Therapeutics Increases Equity Stake in Helomics to 25%
MINNEAPOLIS , March 14, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), formerly Skyline Medical, a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today that it has converted a previous
View HTML
Toggle Summary Precision Therapeutics Investee, Helomics Corporation, Announces Commercial Launch of New ‘HelomicsDiscover’ Program to Drive Forward the Next Generation of Precision Cancer Therapies
MINNEAPOLIS , Aug. 14, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, is pleased to announce that Helomics Corporation , which has a definitive
View HTML
Toggle Summary Precision Therapeutics Investee, Helomics Corporation, Launches Precision Oncology Insights Platform
MINNEAPOLIS , Aug. 09, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, is pleased to announce that Helomics Corporation , which has a definitive
View HTML
Toggle Summary Precision Therapeutics Launches New Website
MINNEAPOLIS , May 31, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today that it has launched a new website:
View HTML
Toggle Summary Precision Therapeutics Projects Meaningful STREAMWAY System Sales in Europe in the Second Half of 2018
MINNEAPOLIS , May 10, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery and producer of the FDA -approved STREAMWAY® System for automated,
View HTML
Toggle Summary Precision Therapeutics Receives $1,370,000 Investment from CEO and Director, Carl Schwartz
MINNEAPOLIS , Jan. 18, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announced that its chief executive officer and director, Carl Schwartz , has made an additional investment of $1,000,000 in the Company, effective January 8, 2019 .
View HTML